Ranjana Advani

Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience
Tan, D., Horning, S. J., Hoppe, R. T., Levy, R., Rosenberg, S. A., & Advani, R. H. (2013). Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience. BLOOD, 122(6), 981-987.

Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
Wang, M. L., Rule, S., Martin, P., Goy, A., Auer, R., & Blum, K. A. (2013). Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma. NEW ENGLAND JOURNAL OF MEDICINE, 369(6), 507-516.

Targeted Therapy in Relapsed Classical Hodgkin Lymphoma
Dinner, S., & Advani, R. (2013). Targeted Therapy in Relapsed Classical Hodgkin Lymphoma. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 11(8), 968-976.

Plasma Epstein-Barr virus DNA predicts outcome in advanced Hodgkin lymphoma: correlative analysis from a large North American cooperative group trial
Kanakry, J. A., Li, H., Gellert, L. L., Lemas, M. V., Hsieh, W.-S., & Ambinder, R. F. (2013). Plasma Epstein-Barr virus DNA predicts outcome in advanced Hodgkin lymphoma: correlative analysis from a large North American cooperative group trial. BLOOD, 121(18), 3547-3553.

Dose-Adjusted EPOCH-Rituximab Therapy in Primary Mediastinal B-Cell Lymphoma
Dunleavy, K., Pittaluga, S., Maeda, L. S., Advani, R., Chen, C. C., & Wilson, W. H. (2013). Dose-Adjusted EPOCH-Rituximab Therapy in Primary Mediastinal B-Cell Lymphoma. NEW ENGLAND JOURNAL OF MEDICINE, 368(15), 1408-1416.

Efficacy of abbreviated Stanford V chemotherapy and involved-field radiotherapy in early-stage Hodgkin lymphoma: mature results of the G4 trial
Advani, R. H., Hoppe, R. T., Baer, D., Mason, J., Warnke, R., & Horning, S. J. (2013). Efficacy of abbreviated Stanford V chemotherapy and involved-field radiotherapy in early-stage Hodgkin lymphoma: mature results of the G4 trial. ANNALS OF ONCOLOGY, 24(4), 1044-1048.

The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496
Evens, A. M., Hong, F., Gordon, L. I., Fisher, R. I., Bartlett, N. L., & Horning, S. J. (2013). The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496. BRITISH JOURNAL OF HAEMATOLOGY, 161(1), 76-86.

Randomized Phase III Trial of ABVD Versus Stanford V With or Without Radiation Therapy in Locally Extensive and Advanced-Stage Hodgkin Lymphoma: An Intergroup Study Coordinated by the Eastern Cooperative Oncology Group (E2496)
Gordon, L. I., Hong, F., Fisher, R. I., Bartlett, N. L., Connors, J. M., & Horning, S. J. (2013). Randomized Phase III Trial of ABVD Versus Stanford V With or Without Radiation Therapy in Locally Extensive and Advanced-Stage Hodgkin Lymphoma: An Intergroup Study Coordinated by the Eastern Cooperative Oncology Group (E2496). JOURNAL OF CLINICAL ONCOLOGY, 31(6), 684-691.

Risk of Therapy-Related Secondary Leukemia in Hodgkin Lymphoma: The Stanford University Experience Over Three Generations of Clinical Trials
Koontz, M. Z., Horning, S. J., Balise, R., Greenberg, P. L., Rosenberg, S. A., & Advani, R. H. (2013). Risk of Therapy-Related Secondary Leukemia in Hodgkin Lymphoma: The Stanford University Experience Over Three Generations of Clinical Trials. JOURNAL OF CLINICAL ONCOLOGY, 31(5), 592-598.

Multicenter phase 1 trial of intraventricular immunochemotherapy in recurrent CNS lymphoma
Rubenstein, J. L., Li, J., Chen, L., Advani, R., Drappatz, J., & Damon, L. E. (2013). Multicenter phase 1 trial of intraventricular immunochemotherapy in recurrent CNS lymphoma. BLOOD, 121(5), 745-751.

Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies
Advani, R. H., Buggy, J. J., Sharman, J. P., Smith, S. M., Boyd, T. E., & Fowler, N. H. (2013). Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies. JOURNAL OF CLINICAL ONCOLOGY, 31(1), 88-94.

Tumor-associated macrophages predict inferior outcomes in classic Hodgkin lymphoma: a correlative study from the E2496 Intergroup trial
Tan, K. L., Scott, D. W., Hong, F., Kahl, B. S., Fisher, R. I., & Gascoyne, R. D. (2012). Tumor-associated macrophages predict inferior outcomes in classic Hodgkin lymphoma: a correlative study from the E2496 Intergroup trial. BLOOD, 120(16), 3280-3287.

Phase II Study of Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Immunochemotherapy Followed by Yttrium-90-Ibritumomab Tiuxetan in Untreated Mantle-Cell Lymphoma: Eastern Cooperative Oncology Group Study E1499
Smith, M. R., Li, H., Gordon, L., Gascoyne, R. D., Paietta, E., & Horning, S. J. (2012). Phase II Study of Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Immunochemotherapy Followed by Yttrium-90-Ibritumomab Tiuxetan in Untreated Mantle-Cell Lymphoma: Eastern Cooperative Oncology Group Study E1499. JOURNAL OF CLINICAL ONCOLOGY, 30(25), 3119-3126.

Brentuximab Vedotin in Transplant-Naive Patients with Relapsed or Refractory Hodgkin Lymphoma: Analysis of Two Phase I Studies
Forero-Torres, A., Fanale, M., Advani, R., Bartlett, N. L., Rosenblatt, J. D., & Younes, A. (2012). Brentuximab Vedotin in Transplant-Naive Patients with Relapsed or Refractory Hodgkin Lymphoma: Analysis of Two Phase I Studies. ONCOLOGIST, 17(8), 1073-1080.

Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study
Pro, B., Advani, R., Brice, P., Bartlett, N. L., Rosenblatt, J. D., & Shustov, A. (2012). Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study. JOURNAL OF CLINICAL ONCOLOGY, 30(18), 2190-2196.

Cardiac toxicity associated with bevacizumab (Avastin) in combination with CHOP chemotherapy for peripheral T cell lymphoma in ECOG 2404 trial
Advani, R. H., Hong, F., Horning, S. J., Kahl, B. S., Manola, J., & Ganjoo, K. (2012). Cardiac toxicity associated with bevacizumab (Avastin) in combination with CHOP chemotherapy for peripheral T cell lymphoma in ECOG 2404 trial. LEUKEMIA & LYMPHOMA, 53(4), 718-720.

STAGE I-IIIA NON-BULKY HODGKIN'S LYMPHOMA. IS FURTHER DISTINCTION BASED ON PROGNOSTIC FACTORS USEFUL? THE STANFORD EXPERIENCE
Advani, R. H., Hoppe, R. T., Maeda, L. S., Baer, D. M., Mason, J., & Horning, S. J. (2011). STAGE I-IIIA NON-BULKY HODGKIN'S LYMPHOMA. IS FURTHER DISTINCTION BASED ON PROGNOSTIC FACTORS USEFUL? THE STANFORD EXPERIENCE. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 81(5), 1374-1379.

MicroRNAs Are Independent Predictors of Outcome in Diffuse Large B-Cell Lymphoma Patients Treated with R-CHOP
Alencar, A. J., Malumbres, R., Kozloski, G. A., Advani, R., Talreja, N., & Lossos, I. S. (2011). MicroRNAs Are Independent Predictors of Outcome in Diffuse Large B-Cell Lymphoma Patients Treated with R-CHOP. CLINICAL CANCER RESEARCH, 17(12), 4125-4135.

Current concepts and controversies in the management of early stage Hodgkin lymphoma
Maeda, L. S., Lee, M., & Advani, R. H. (2011). Current concepts and controversies in the management of early stage Hodgkin lymphoma. LEUKEMIA & LYMPHOMA, 52(6), 962-971.

Optimal therapy of advanced Hodgkin lymphoma.
Advani, R. (2011). Optimal therapy of advanced Hodgkin lymphoma. Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program, 2011, 310-316.

Comparison of conventional prognostic indices in patients older than 60 years with diffuse large B-cell lymphoma treated with R-CHOP in the US Intergroup Study (ECOG 4494, CALGB 9793): consideration of age greater than 70 years in an elderly prognostic index (E-IPI)
Advani, R. H., Chen, H., Habermann, T. M., Morrison, V. A., Weller, E. A., & Horning, S. J. (2010). Comparison of conventional prognostic indices in patients older than 60 years with diffuse large B-cell lymphoma treated with R-CHOP in the US Intergroup Study (ECOG 4494, CALGB 9793): consideration of age greater than 70 years in an elderly prognostic index (E-IPI). BRITISH JOURNAL OF HAEMATOLOGY, 151(2), 143-151.

Risk stratification in extranodal natural killer/T-cell lymphoma
Kohrt, H., Lee, M., & Advani, R. (2010). Risk stratification in extranodal natural killer/T-cell lymphoma. EXPERT REVIEW OF ANTICANCER THERAPY, 10(9), 1395-1405.

Prediction of Survival in Diffuse Large B-Cell Lymphoma Based On the Expression of Two Genes: Integration of Tumor and Microenvironment Contributions
Alizadeh, A. A., Gentles, A. J., Alencar, A. J., Kohrt, H. E., Houot, R., & Levy, R. (2009). Prediction of Survival in Diffuse Large B-Cell Lymphoma Based On the Expression of Two Genes: Integration of Tumor and Microenvironment Contributions. BLOOD, 114(22), 258-258.

Management of T-cell and natural-killer-cell neoplasms in Asia: consensus statement from the Asian Oncology Summit 2009
Kwong, Y.-L., Anderson, B. O., Advani, R., Kim, W.-S., Levine, A. M., & Lim, S.-T. (2009). Management of T-cell and natural-killer-cell neoplasms in Asia: consensus statement from the Asian Oncology Summit 2009. LANCET ONCOLOGY, 10(11), 1093-1101.

Phase I Study of the Humanized Anti-CD40 Monoclonal Antibody Dacetuzumab in Refractory or Recurrent Non-Hodgkin's Lymphoma
Advani, R., Forero-Torres, A., Furman, R. R., Rosenblatt, J. D., Younes, A., & Drachman, J. G. (2009). Phase I Study of the Humanized Anti-CD40 Monoclonal Antibody Dacetuzumab in Refractory or Recurrent Non-Hodgkin's Lymphoma. JOURNAL OF CLINICAL ONCOLOGY, 27(26), 4371-4377.

Impact of positive positron emission tomography on prediction of freedom from progression after Stanford V chemotherapy in Hodgkin's disease
Advani, R., Maeda, L., Lavori, P., Quon, A., Hoppe, R., & Horning, S. J. (2007). Impact of positive positron emission tomography on prediction of freedom from progression after Stanford V chemotherapy in Hodgkin's disease. JOURNAL OF CLINICAL ONCOLOGY, 25(25), 3902-3907.

Angioimmunoblastic T cell lymphoma: Treatment experience with cyclosporine
Advani, R., Horwitz, S., Zelenetz, A., & Horning, S. J. (2007). Angioimmunoblastic T cell lymphoma: Treatment experience with cyclosporine. LEUKEMIA & LYMPHOMA, 48(3), 521-525.

Stage I and II follicular non-Hodgkin's lymphoma: Long-term follow-up of no initial therapy
Advani, R., Rosenberg, S. A., & Horning, S. J. (2004). Stage I and II follicular non-Hodgkin's lymphoma: Long-term follow-up of no initial therapy. JOURNAL OF CLINICAL ONCOLOGY, 22(8), 1454-1459.

Brentuximab Vedotin in the Front-Line Treatment of Patients With CD30(+) Peripheral T-Cell Lymphomas: Results of a Phase I Study
Fanale, M. A., Horwitz, S. M., Forero-Torres, A., Bartlett, N. L., Advani, R. H., & Shustov, A. R. (2014). Brentuximab Vedotin in the Front-Line Treatment of Patients With CD30(+) Peripheral T-Cell Lymphomas: Results of a Phase I Study. JOURNAL OF CLINICAL ONCOLOGY, 32(28), 3137-?.

Non-Hodgkin's Lymphomas, Version 4.2014.
Zelenetz, A. D., Gordon, L. I., Wierda, W. G., Abramson, J. S., Advani, R. H., & Sundar, H. (2014). Non-Hodgkin's Lymphomas, Version 4.2014. Journal of the National Comprehensive Cancer Network , 12(9), 1282-1303.

ACR Appropriateness Criteria (R) W Pediatric Hodgkin Lymphoma
Terezakis, S. A., Metzger, M. L., Hodgson, D. C., Schwartz, C. L., Advani, R., & Constine, L. S. (2014). ACR Appropriateness Criteria (R) W Pediatric Hodgkin Lymphoma. PEDIATRIC BLOOD & CANCER, 61(7), 1305-1312.

A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factors
de Vos, S., Forero-Torres, A., Ansell, S. M., Kahl, B., Cheson, B. D., & Advani, R. (2014). A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factors. JOURNAL OF HEMATOLOGY & ONCOLOGY, 7.

Non-Hodgkin's Lymphomas, Version 2.2014
Zelenetz, A. D., Gordon, L. I., Wierda, W. G., Abramson, J. S., Advani, R. H., & Sundar, H. (2014). Non-Hodgkin's Lymphomas, Version 2.2014. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 12(6), 916-945.

A multicentre study of primary breast diffuse large B-cell lymphoma in the rituximab era
Hosein, P. J., Maragulia, J. C., Salzberg, M. P., Press, O. W., Habermann, T. M., & Lossos, I. S. (2014). A multicentre study of primary breast diffuse large B-cell lymphoma in the rituximab era. BRITISH JOURNAL OF HAEMATOLOGY, 165(3), 358-363.

Bevacizumab and cyclosphosphamide, doxorubicin, vincristine and prednisone in combination for patients with peripheral T-cell or natural killer cell neoplasms: an Eastern Cooperative Oncology Group study (E2404)
Ganjoo, K., Hong, F., Horning, S. J., Gascoyne, R. D., Natkunam, Y., & Advani, R. H. (2014). Bevacizumab and cyclosphosphamide, doxorubicin, vincristine and prednisone in combination for patients with peripheral T-cell or natural killer cell neoplasms: an Eastern Cooperative Oncology Group study (E2404). LEUKEMIA & LYMPHOMA, 55(4), 768-772.

Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies
Bartlett, N. L., Chen, R., Fanale, M. A., Brice, P., Gopal, A., & Forero-Torres, A. (2014). Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies. JOURNAL OF HEMATOLOGY & ONCOLOGY, 7.

A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factors.
de Vos, S., Forero-Torres, A., Ansell, S. M., Kahl, B., Cheson, B. D., & Advani, R. (2014). A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factors. Journal of hematology & oncology, 7(1), 44-?.

Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies.
Bartlett, N. L., Chen, R., Fanale, M. A., Brice, P., Gopal, A., & Forero-Torres, A. (2014). Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies. Journal of hematology & oncology, 7, 24-?.

Lymphoma occurring during pregnancy: antenatal therapy, complications, and maternal survival in a multicenter analysis.
Evens, A. M., Advani, R., Press, O. W., Lossos, I. S., Vose, J. M., & Bartlett, N. L. (2013). Lymphoma occurring during pregnancy: antenatal therapy, complications, and maternal survival in a multicenter analysis. Journal of clinical oncology , 31(32), 4132-4139.

ACR APPROPRIATENESS CRITERIA (R) Localized Nodal Indolent Lymphoma
Hoppe, B. S., Hodgson, D. C., Advani, R., Dabaja, B. S., Flowers, C. R., & Constine, L. S. (2013). ACR APPROPRIATENESS CRITERIA (R) Localized Nodal Indolent Lymphoma. ONCOLOGY-NEW YORK, 27(8), 786-794.

ACR Appropriateness Criteria: Localized nodal indolent lymphoma.
Hoppe, B. S., Hodgson, D. C., Advani, R., Dabaja, B. S., Flowers, C. R., & Constine, L. S. (2013). ACR Appropriateness Criteria: Localized nodal indolent lymphoma. Oncology (Williston Park, N.Y.), 27(8), 786-794.

A multicenter phase II trial to determine the safety and efficacy of combination therapy with denileukin diftitox and cyclophosphamide, doxorubicin, vincristine and prednisone in untreated peripheral T-cell lymphoma: the CONCEPT study
Foss, F. M., Sjak-Shie, N., Goy, A., Jacobsen, E., Advani, R., & Bolejack, V. (2013). A multicenter phase II trial to determine the safety and efficacy of combination therapy with denileukin diftitox and cyclophosphamide, doxorubicin, vincristine and prednisone in untreated peripheral T-cell lymphoma: the CONCEPT study. LEUKEMIA & LYMPHOMA, 54(7), 1373-1379.

Non-Hodgkin's Lymphomas, Version 1.2013 Featured Updates to the NCCN Guidelines
Zelenetz, A. D., Wierda, W. G., Abramson, J. S., Advani, R. H., Andreadis, C. B., & Naganuma, M. (2013). Non-Hodgkin's Lymphomas, Version 1.2013 Featured Updates to the NCCN Guidelines. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 11(3), 257-273.

Non-Hodgkin's lymphomas, version 1.2013.
Zelenetz, A. D., Wierda, W. G., Abramson, J. S., Advani, R. H., Andreadis, C. B., & Naganuma, M. (2013). Non-Hodgkin's lymphomas, version 1.2013. Journal of the National Comprehensive Cancer Network , 11(3), 257-272.

Gene Expression-Based Model Using Formalin-Fixed Paraffin-Embedded Biopsies Predicts Overall Survival in Advanced-Stage Classical Hodgkin Lymphoma
Scott, D. W., Chan, F. C., Hong, F., Rogic, S., Tan, K. L., & Gascoyne, R. D. (2013). Gene Expression-Based Model Using Formalin-Fixed Paraffin-Embedded Biopsies Predicts Overall Survival in Advanced-Stage Classical Hodgkin Lymphoma. JOURNAL OF CLINICAL ONCOLOGY, 31(6), 692-700.

Non-Hodgkin's Lymphomas, version 3.2012.
Zelenetz, A. D., Wierda, W. G., Abramson, J. S., Advani, R. H., Andreadis, C. B., & Dwyer, M. A. (2012). Non-Hodgkin's Lymphomas, version 3.2012. Journal of the National Comprehensive Cancer Network , 10(12), 1487-1498.

Non-Hodgkin's Lymphomas, Version 3.2012 Featured Updates to the NCCN Guidelines
Zelenetz, A. D., Wierda, W. G., Abramson, J. S., Advani, R. H., Andreadis, C. B., & Dwyer, M. A. (2012). Non-Hodgkin's Lymphomas, Version 3.2012 Featured Updates to the NCCN Guidelines. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 10(12), 1487-1498.

Single Cell Profiling of Circulating Tumor Cells: Transcriptional Heterogeneity and Diversity from Breast Cancer Cell Lines
Powell, A. A., Talasaz, Aa. H., Zhang, H., Coram, M. A., Reddy, A., & Jeffrey, S. S. (2012). Single Cell Profiling of Circulating Tumor Cells: Transcriptional Heterogeneity and Diversity from Breast Cancer Cell Lines. PLOS ONE, 7(5).

Hodgkin Lymphoma, Version 2.2012 Featured Updates to the NCCN Guidelines
Hoppe, R. T., Advani, R. H., Ai, W. Z., Ambinder, R. F., Aoun, P., & Sundar, H. (2012). Hodgkin Lymphoma, Version 2.2012 Featured Updates to the NCCN Guidelines. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 10(5), 589-597.

Interim-treatment quantitative PET parameters predict progression and death among patients with hodgkin's disease
Tseng, D., Rachakonda, L. P., Su, Z., Advani, R., Horning, S., & Tran, P. T. (2012). Interim-treatment quantitative PET parameters predict progression and death among patients with hodgkin's disease. RADIATION ONCOLOGY, 7.

In situ vaccination against mycosis fungoides by intratumoral injection of a TLR9 agonist combined with radiation: a phase 1/2 study
Kim, Y. H., Gratzinger, D., Harrison, C., Brody, J. D., Czerwinski, D. K., & Levy, R. (2012). In situ vaccination against mycosis fungoides by intratumoral injection of a TLR9 agonist combined with radiation: a phase 1/2 study. BLOOD, 119(2), 355-363.

A Phase I Weekly Dosing Study of Brentuximab Vedotin in Patients with Relapsed/Refractory CD30-Positive Hematologic Malignancies
Fanale, M. A., Forero-Torres, A., Rosenblatt, J. D., Advani, R. H., Franklin, A. R., & Bartlett, N. L. (2012). A Phase I Weekly Dosing Study of Brentuximab Vedotin in Patients with Relapsed/Refractory CD30-Positive Hematologic Malignancies. CLINICAL CANCER RESEARCH, 18(1), 248-255.

Phase I trial of oblimersen (GenasenseA (R)) and gemcitabine in refractory and advanced malignancies
Galatin, P. S., Advani, R. H., Fisher, G. A., Francisco, B., Julian, T., & Sikic, B. I. (2011). Phase I trial of oblimersen (GenasenseA (R)) and gemcitabine in refractory and advanced malignancies. INVESTIGATIONAL NEW DRUGS, 29(5), 971-977.

Hodgkin lymphoma.
Hoppe, R. T., Advani, R. H., Ai, W. Z., Ambinder, R. F., Bello, C. M., & Yahalom, J. (2011). Hodgkin lymphoma. Journal of the National Comprehensive Cancer Network , 9(9), 1020-1058.

NCCN Clinical Practice Guidelines in Oncology for Hodgkin Lymphoma
Hoppe, R. T., Advani, R. H., Ai, W. Z., Ambinder, R. F., Bello, C. M., & Yahalom, J. (2011). NCCN Clinical Practice Guidelines in Oncology for Hodgkin Lymphoma. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 9(9), 1020-1058.

Prediction of survival in diffuse large B-cell lymphoma based on the expression of 2 genes reflecting tumor and microenvironment
Alizadeh, A. A., Gentles, A. J., Alencar, A. J., Liu, C. L., Kohrt, H. E., & Levy, R. (2011). Prediction of survival in diffuse large B-cell lymphoma based on the expression of 2 genes reflecting tumor and microenvironment. BLOOD, 118(5), 1350-1358.

Lymphoma in Pregnancy Initially Diagnosed as Vaginal Intraepithelial Neoplasia and Lichen Planus
Thuong-Thuong Nguyen, T. T., Gubens, M., Arber, D. A., Advani, R., Juretzka, M., & Aziz, N. (2011). Lymphoma in Pregnancy Initially Diagnosed as Vaginal Intraepithelial Neoplasia and Lichen Planus. OBSTETRICS AND GYNECOLOGY, 118(2), 486-489.

Non-Hodgkin's Lymphomas
Zelenetz, A. D., Abramson, J. S., Advani, R. H., Andreadis, C. B., Bartlett, N., & Zafar, N. (2011). Non-Hodgkin's Lymphomas. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 9(5), 484-560.

ACR Appropriateness Criteria (R) on Hodgkin's Lymphoma-Unfavorable Clinical Stage I and II
Das, P., Ng, A., Constine, L. S., Advani, R., Flowers, C., & Yunes, M. J. (2011). ACR Appropriateness Criteria (R) on Hodgkin's Lymphoma-Unfavorable Clinical Stage I and II. JOURNAL OF THE AMERICAN COLLEGE OF RADIOLOGY, 8(5), 302-308.

CD40 Pathway Activation Status Predicts Response to CD40 Therapy in Diffuse Large B Cell Lymphoma
Burington, B., Yue, P., Shi, X., Advani, R., Lau, J. T., & Dornan, D. (2011). CD40 Pathway Activation Status Predicts Response to CD40 Therapy in Diffuse Large B Cell Lymphoma. SCIENCE TRANSLATIONAL MEDICINE, 3(74).

Prediction of Survival In Diffuse Large B-Cell Lymphoma Based On the Expression of Two Genes Reflecting Tumor and Microenvironment
Alizadeh, A. A., Gentles, A. J., Alencar, A. J., Kohrt, H. E., Houot, R., & Levy, R. (2010). Prediction of Survival In Diffuse Large B-Cell Lymphoma Based On the Expression of Two Genes Reflecting Tumor and Microenvironment. BLOOD, 116(21), 836-837.

In Situ Vaccination With a TLR9 Agonist Induces Systemic Lymphoma Regression: A Phase I/II Study
Brody, J. D., Ai, W. Z., Czerwinski, D. K., Torchia, J. A., Levy, M., & Levy, R. (2010). In Situ Vaccination With a TLR9 Agonist Induces Systemic Lymphoma Regression: A Phase I/II Study. JOURNAL OF CLINICAL ONCOLOGY, 28(28), 4324-4332.

ACR Appropriateness Criteria (R): Follow-Up of Hodgkin's Lymphoma
Ng, A., Constine, L. S., Advani, R., Das, P., Flowers, C., & Yunes, M. J. (2010). ACR Appropriateness Criteria (R): Follow-Up of Hodgkin's Lymphoma. CURRENT PROBLEMS IN CANCER, 34(3), 211-227.

Voreloxin, a First-in-Class Anticancer Quinolone Derivative, in Relapsed/Refractory Solid Tumors: A Report on Two Dosing Schedules
Advani, R. H., Hurwitz, H. I., Gordon, M. S., Ebbinghaus, S. W., Mendelson, D. S., & Adelman, D. C. (2010). Voreloxin, a First-in-Class Anticancer Quinolone Derivative, in Relapsed/Refractory Solid Tumors: A Report on Two Dosing Schedules. CLINICAL CANCER RESEARCH, 16(7), 2167-2175.

Non-Hodgkin's Lymphomas
Zelenetz, A. D., Abramson, J. S., Advani, R. H., Andreadis, C. B., Byrd, J. C., & Yunus, F. (2010). Non-Hodgkin's Lymphomas. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 8(3), 288-334.

NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's lymphomas.
Zelenetz, A. D., Abramson, J. S., Advani, R. H., Andreadis, C. B., Byrd, J. C., & Yunus, F. (2010). NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's lymphomas. Journal of the National Comprehensive Cancer Network , 8(3), 288-334.

Interim positron emission tomography scans in diffuse large B-cell lymphoma: an independent expert nuclear medicine evaluation of the Eastern Cooperative Oncology Group E3404 study
Horning, S. J., Juweid, M. E., Schoeder, H., Wiseman, G., McMillan, A., & Quon, A. (2010). Interim positron emission tomography scans in diffuse large B-cell lymphoma: an independent expert nuclear medicine evaluation of the Eastern Cooperative Oncology Group E3404 study. BLOOD, 115(4), 775-777.

Lymphoma cell VEGFR2 expression detected by immunohistochemistry predicts poor overall survival in diffuse large B cell lymphoma treated with immunochemotherapy (R-CHOP)
Gratzinger, D., Advani, R., Zhao, S., Talreja, N., Tibshirani, R. J., & Natkunam, Y. (2010). Lymphoma cell VEGFR2 expression detected by immunohistochemistry predicts poor overall survival in diffuse large B cell lymphoma treated with immunochemotherapy (R-CHOP). BRITISH JOURNAL OF HAEMATOLOGY, 148(2), 235-244.

The emerging role for rituximab in the treatment of nodular lymphocyte predominant Hodgkin lymphoma
Maeda, L. S., & Advani, R. H. (2009). The emerging role for rituximab in the treatment of nodular lymphocyte predominant Hodgkin lymphoma. CURRENT OPINION IN ONCOLOGY, 21(5), 397-400.

Prognostic Factors in Primary Cutaneous Anaplastic Large Cell Lymphoma Characterization of Clinical Subset With Worse Outcome
Woo, D. K., Jones, C. R., Vanoli-Storz, M. N., Kohler, S., Reddy, S., & Kim, Y. H. (2009). Prognostic Factors in Primary Cutaneous Anaplastic Large Cell Lymphoma Characterization of Clinical Subset With Worse Outcome. ARCHIVES OF DERMATOLOGY, 145(6), 667-674.

Prognostic significance of vascular endothelial growth factor (VEGF), VEGF receptors (VEGFR), and vascularity in diffuse large B-cell lymphoma treated with immunochemotherapy (R-CHOP)
Gratzinger, D., Advani, R., Zhao, S., Talreja, N., Tibshirani, R. J., & Natkunam, Y. (2009). Prognostic significance of vascular endothelial growth factor (VEGF), VEGF receptors (VEGFR), and vascularity in diffuse large B-cell lymphoma treated with immunochemotherapy (R-CHOP). JOURNAL OF CLINICAL ONCOLOGY, 27(15).

Targeting CD40 in Waldenstrom's Macroglobulinemia
Lee, M., & Advani, R. (2009). Targeting CD40 in Waldenstrom's Macroglobulinemia. CLINICAL LYMPHOMA & MYELOMA, 9(1), 87-89.

Extranodal natural killer/T-cell lymphoma: current concepts in biology and treatment
Kohrt, H., & Advani, R. (2009). Extranodal natural killer/T-cell lymphoma: current concepts in biology and treatment. LEUKEMIA & LYMPHOMA, 50(11), 1773-1784.

Dynamic CD8 T-Cell Responses to Tumor-Associated Epstein-Barr Virus Antigens in Patients With Epstein-Barr Virus-Negative Hodgkin's Disease
Kohrt, H., Johannsen, A., Hoppe, R., Horning, S. J., Rosenberg, S. A., & Lee, P. P. (2009). Dynamic CD8 T-Cell Responses to Tumor-Associated Epstein-Barr Virus Antigens in Patients With Epstein-Barr Virus-Negative Hodgkin's Disease. ONCOLOGY RESEARCH, 18(5-6), 287-292.

Indolent primary cutaneous B-cell lymphoma: Experience using systemic rituximab
Morales, A. V., Advani, R., Horwitz, S. M., Riaz, N., Reddy, S., & Kim, Y. H. (2008). Indolent primary cutaneous B-cell lymphoma: Experience using systemic rituximab. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 59(6), 953-957.

Evaluation and management of angioimmunoblastic T-cell lymphoma: a review of current approaches and future strategies.
Alizadeh, A. A., & Advani, R. H. (2008). Evaluation and management of angioimmunoblastic T-cell lymphoma: a review of current approaches and future strategies. Clinical advances in hematology & oncology : H&O, 6(12), 899-909.

Hodgkin disease/lymphoma.
Hoppe, R. T., Advani, R. H., Ambinder, R. F., Bierman, P. J., Bloomfield, C. D., & Zelenetz, A. D. (2008). Hodgkin disease/lymphoma. Journal of the National Comprehensive Cancer Network , 6(6), 594-622.

Paraffin-based 6-gene model predicts outcome in diffuse large B-cell lymphoma patients treated with R-CHOP
Malumbres, R., Chen, J., Tibshirani, R., Johnson, N. A., Sehn, L. H., & Lossos, I. S. (2008). Paraffin-based 6-gene model predicts outcome in diffuse large B-cell lymphoma patients treated with R-CHOP. BLOOD, 111(12), 5509-5514.

Beyond the guidelines in the treatment of peripheral T-cell lymphoma: new drug development.
Chen, A. I., & Advani, R. H. (2008). Beyond the guidelines in the treatment of peripheral T-cell lymphoma: new drug development. Journal of the National Comprehensive Cancer Network , 6(4), 428-435.

Non-Hodgkin's lymphomas.
Zelenetz, A. D., Advani, R. H., Byrd, J. C., Czuczman, M. S., Damon, L. E., & Yunus, F. (2008). Non-Hodgkin's lymphomas. Journal of the National Comprehensive Cancer Network , 6(4), 356-421.

Non-Hodgkin lymphoma of the breast
Ganjoo, K., Advani, R., Mariappan, M. R., McMillan, A., & Horning, S. (2007). Non-Hodgkin lymphoma of the breast. CANCER, 110(1), 25-30.

Treatment of mantle cell lymphoma: Current approach and future directions
Brody, J., & Advani, R. (2006). Treatment of mantle cell lymphoma: Current approach and future directions. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 58(3), 257-265.

Staging accuracy in mycosis fungoides and Sezary syndrome using integrated positron emission tomography and computed tomography
Tsai, E. Y., Taur, A., Espinosa, L., Quon, A., Johnson, D., & Kim, Y. H. (2006). Staging accuracy in mycosis fungoides and Sezary syndrome using integrated positron emission tomography and computed tomography. ARCHIVES OF DERMATOLOGY, 142(5), 577-584.

Management of advanced stage Hodgkin lymphoma.
Advani, R., Ai, W. Z., & Horning, S. J. (2006). Management of advanced stage Hodgkin lymphoma. Journal of the National Comprehensive Cancer Network , 4(3), 241-247.

Non-Hodgkin's lymphoma. Clinical practice guidelines in oncology.
Zelenetz, A. D., Advani, R. H., Buadi, F., Cabanillas, F., Caligiuri, M. A., & Yahalom, J. (2006). Non-Hodgkin's lymphoma. Clinical practice guidelines in oncology. Journal of the National Comprehensive Cancer Network , 4(3), 258-310.

Hodgkin disease/lymphoma. Clinical practice guidelines in oncology.
Hoppe, R. T., Advani, R. H., Bierman, P. J., Bloomfield, C. D., Buadi, F., & Zelenetz, A. D. (2006). Hodgkin disease/lymphoma. Clinical practice guidelines in oncology. Journal of the National Comprehensive Cancer Network , 4(3), 210-230.

A phase I trial of liposomal doxorubicin, paclitaxel and valspodar (PSC-833), an inhibitor of multidrug resistance
Advani, R., Lum, B. L., Fisher, G. A., Halsey, J., Chin, D. L., & Sikic, B. I. (2005). A phase I trial of liposomal doxorubicin, paclitaxel and valspodar (PSC-833), an inhibitor of multidrug resistance. ANNALS OF ONCOLOGY, 16(12), 1968-1973.

A phase I trial of aprinocarsen (ISIS 3521/LY900003), an antisense inhibitor of protein kinase C-alpha administered as a 24-hour weekly infusion schedule in patients with advanced cancer
Advani, R., Lum, B. L., Fisher, G. A., Halsey, J., Geary, R. S., & Sikic, B. I. (2005). A phase I trial of aprinocarsen (ISIS 3521/LY900003), an antisense inhibitor of protein kinase C-alpha administered as a 24-hour weekly infusion schedule in patients with advanced cancer. INVESTIGATIONAL NEW DRUGS, 23(5), 467-477.

A Phase I Trial of Aprinocarsen (ISIS 3521/LY900003), an Antisense Inhibitor of Protein Kinase C-alpha Administered as a 24-hour Weekly Infusion Schedule in Patients with Advanced Cancer.
Advani R, Lum BL, Fisher GA, Halsey J, Geary RS, & Sikic BI. (2005). A Phase I Trial of Aprinocarsen (ISIS 3521/LY900003), an Antisense Inhibitor of Protein Kinase C-alpha Administered as a 24-hour Weekly Infusion Schedule in Patients with Advanced Cancer. Investigational New Drugs,, In Press.

Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: A phase III trial (E2995)
Greenberg, P. L., Lee, S. J., Advani, R., Tallman, M. S., Sikic, B. I., & Rowe, J. M. (2004). Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: A phase III trial (E2995). JOURNAL OF CLINICAL ONCOLOGY, 22(6), 1078-1086.

Phase I and pharmacokinetic study of BMS-188797, a new taxane analog, administered on a weekly schedule in patients with advanced malignancies
Advani, R., Fisher, G. A., Lum, B. L., Jambalos, C., Cho, C. D., & Sikic, B. I. (2003). Phase I and pharmacokinetic study of BMS-188797, a new taxane analog, administered on a weekly schedule in patients with advanced malignancies. CLINICAL CANCER RESEARCH, 9(14), 5187-5194.

A phase I trial of doxorubicin, paclitaxel, and valspodar (PSC 833), a modulator of multidrug resistance
Advani, R., Fisher, G. A., Lum, B. L., Hausdorff, J., Halsey, J., & Sikic, B. I. (2001). A phase I trial of doxorubicin, paclitaxel, and valspodar (PSC 833), a modulator of multidrug resistance. CLINICAL CANCER RESEARCH, 7(5), 1221-1229.

Treatment of refractory and relapsed acute myelogenous leukemia with combination chemotherapy plus the multidrug resistance modulator PSC 833 (Valspodar).
Advani R, Saba HI, Tallman M, Rowe JM, Wiernik PH, & Greenberg P. (1999). Treatment of refractory and relapsed acute myelogenous leukemia with combination chemotherapy plus the multidrug resistance modulator PSC 833 (Valspodar). Blood, 93.

View All 96 Publications